Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 9/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | MC4R | P32245 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242183 | 0.89 | PTGS2 (0.81) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL3873376 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL13524327 | 0.85 | PTGS2 (0.75) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL2159864 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL6739514 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL3246743 | 0.84 | PTGS2 (0.73) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL6726009 | 0.84 | PTGS1 (0.72) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL3246262 | 0.84 | PTGS2 (0.74) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL3247612 | 0.84 | PTGS2 (0.74) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| Rofecoxib SCHEMBL4434618 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010062927-A2 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | WO | claimed |
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| EP-1349548-A4 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO INC (US) | 2004-06-02 | — | — | EP | claimed |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | HARTMAN GEORGE D (US) | 2004-03-18 | — | — | US | claimed |
| EP-1349548-A2 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | Merck & Co., Inc. (US) | 2003-10-08 | — | — | EP | claimed |
| US-6593361-B2 | Retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma via administering nontoxic amount of non- steroidal antiinflammatory agent which inhibits prostaglandin G/H synthase | MERCK FROSST COMPANY (CA) | 2003-07-15 | — | — | US | claimed |
| WO-2002053099-A2 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO., INC. (US) | 2002-07-11 | — | — | WO | claimed |
| US-20020045605-A1 | Method of treating colonic adenomas | MERCK & CO. | 2002-04-18 | — | — | US | claimed |
| US-20020042375-A1 | Method of treating cancer | HEIMBROOK DAVID C (US) | 2002-04-11 | — | — | US | claimed |
| US-20010016595-A1 | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases | MERCK FROSST CANADA INC./MERCK FROSST CANADA & CO. | 2001-08-23 | — | — | US | claimed |
| EP-0853481-A1 | COMPOSITIONS FOR TREATING INFLAMMATION CONTAINING CERTAIN PROSTAGLANDINS AND A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | MERCK FROSST CANADA INC. (CA) | 1998-07-22 | — | — | EP | claimed |
| EP-0705254-B1 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC (CA) | 1998-05-06 | — | — | EP | claimed |
| EP-0822190-A1 | Phenyl heterocycles as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC. (CA) | 1998-02-04 | — | — | EP | claimed |
| WO-1997011701-A1 | COMPOSITIONS FOR TREATING INFLAMMATION CONTAINING CERTAIN PROSTAGLANDINS AND A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | MERCK-FROSST CANADA INC. (CA) | 1997-04-03 | — | — | WO | claimed |
| CN-1143365-A | Phenyl-heterocycles as COX-2 inhibitors | MERCK FROSST CANADA INC (CA) | 1997-02-19 | — | — | CN | claimed |
| EP-0754687-A1 | Phenyl heterocycles as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC. (CA) | 1997-01-22 | — | — | EP | claimed |
| CN-1125944-A | Phenyl heterocyclic compounds useful as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC (CA) | 1996-07-03 | — | — | CN | claimed |
| EP-0705254-A1 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-04-10 | — | — | EP | claimed |
| US-5474995-A | Nonsteroidal, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1995-12-12 | — | — | US | claimed |
| WO-1995000501-A2 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1995-01-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016595-A1 | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases | PTGS1, PTGES2, PTGS2 | PTGS2 3/4885PTGS1 1/4885ABCB11 1435/4885 |
| US-20020045605-A1 | Method of treating colonic adenomas | FAP, APC, PTGS2 | PTGS2 3/4885PTGS1 5/4885ABCB11 1667/4885 |
| US-20020042375-A1 | Method of treating cancer | ACP3, KLK3, FOLH1 | PTGS2 14/4885PTGS1 20/4885ABCB11 1357/4885 |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | ITGB3, ITGB5, ITGB2 | PTGS2 27/4885PTGS1 45/4885ABCB11 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.